Published in Gynecol Oncol on May 02, 2008
Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl Oncol (2010) 1.31
FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer (2011) 1.24
Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors. Semin Cancer Biol (2010) 1.21
Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer (2009) 1.17
Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol (2013) 1.06
Regulation of cell adhesion and migration by cell-derived matrices. Exp Cell Res (2013) 1.00
The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh Migr (2012) 0.99
Electrotaxis of lung cancer cells in ordered three-dimensional scaffolds. Biomicrofluidics (2012) 0.98
Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One (2011) 0.95
Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv Drug Deliv Rev (2013) 0.89
Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene (2013) 0.89
Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One (2011) 0.89
Organotypic modelling as a means of investigating epithelial-stromal interactions during tumourigenesis. Fibrogenesis Tissue Repair (2008) 0.88
Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice. J Ovarian Res (2014) 0.84
Cdc42 regulates extracellular matrix remodeling in three dimensions. J Biol Chem (2011) 0.83
Human gingival fibroblasts display a non-fibrotic phenotype distinct from skin fibroblasts in three-dimensional cultures. PLoS One (2014) 0.82
Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology. Glycobiology (2011) 0.81
Palladin mediates stiffness-induced fibroblast activation in the tumor microenvironment. Biophys J (2015) 0.80
Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. PLoS One (2014) 0.79
TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC. Oncotarget (2017) 0.75
Cell-derived matrices for studying cell proliferation and directional migration in a complex 3D microenvironment. Nat Protoc (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
Tensional homeostasis and the malignant phenotype. Cancer Cell (2005) 19.30
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Taking cell-matrix adhesions to the third dimension. Science (2001) 15.21
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell (2005) 12.73
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol (2005) 11.74
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
Modeling tissue morphogenesis and cancer in 3D. Cell (2007) 7.49
The myofibroblast in wound healing and fibrocontractive diseases. J Pathol (2003) 6.16
Formation and function of the myofibroblast during tissue repair. J Invest Dermatol (2007) 6.11
Cell interactions with three-dimensional matrices. Curr Opin Cell Biol (2002) 4.34
ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J Cell Biol (2003) 4.24
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
Engineering tumors with 3D scaffolds. Nat Methods (2007) 3.96
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res (2002) 3.94
The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci (2004) 3.83
The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest (2007) 3.39
The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol (2004) 3.34
Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A (2007) 3.26
Reactive stroma in prostate cancer progression. J Urol (2001) 3.21
Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer (2003) 3.02
Tumor-stroma interactions. Curr Opin Genet Dev (2005) 2.89
Mechanobiology in the third dimension. Ann Biomed Eng (2005) 2.89
Determination of cellular shape by the extracellular matrix and its correlation with the control of cellular growth. Cancer Res (1978) 2.86
Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem (2007) 2.81
The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol (2006) 2.58
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol (2003) 2.43
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43
Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol (2005) 2.02
Modulation of fibroblast morphology and adhesion during collagen matrix remodeling. Mol Biol Cell (2002) 1.92
Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol (2002) 1.84
Microtubule function in fibroblast spreading is modulated according to the tension state of cell-matrix interactions. Proc Natl Acad Sci U S A (2007) 1.80
Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol (2005) 1.77
Nested collagen matrices: a new model to study migration of human fibroblast populations in three dimensions. Exp Cell Res (2005) 1.58
Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol (2006) 1.46
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Dimensions and dynamics in integrin function. Braz J Med Biol Res (2003) 1.43
The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci U S A (1985) 1.40
Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation (2002) 1.36
Genomic analysis of smooth muscle cells in 3-dimensional collagen matrix. FASEB J (2002) 1.33
The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas (2004) 1.31
Melanoma development and progression: a conspiracy between tumor and host. Differentiation (2002) 1.30
Cell-matrix entanglement and mechanical anchorage of fibroblasts in three-dimensional collagen matrices. Mol Biol Cell (2005) 1.28
Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods Mol Biol (2009) 1.27
Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem (2004) 1.24
Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections. Cancer Res (1990) 1.24
Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene (2003) 1.23
Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol (2002) 1.22
Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol (2001) 1.22
Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer (2003) 1.21
FAK-dependent regulation of myofibroblast differentiation. FASEB J (2006) 1.17
Emergentism as a default: cancer as a problem of tissue organization. J Biosci (2005) 1.12
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Morphology, cytoskeletal organization, and myosin dynamics of mouse embryonic fibroblasts cultured on nanofibrillar surfaces. Mol Cell Biochem (2007) 1.04
Modelling molecular mechanisms of breast cancer and invasion: lessons from the normal gland. Biochem Soc Trans (2007) 1.04
Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol (2005) 1.03
Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol (2005) 1.03
Three-dimensional culture regulates Raf-1 expression to modulate fibronectin matrix assembly. Mol Biol Cell (2006) 0.99
Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers. Semin Cancer Biol (2005) 0.95
Desmoplastic breast carcinoma as a source of human myofibroblasts. Am J Pathol (1984) 0.94
Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer (2002) 0.92
Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol (2001) 0.91
Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. Int J Cancer (2001) 0.90
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT). Br J Cancer (2003) 0.86
Smooth muscle differentiation in normal human ovaries, ovarian stromal hyperplasia and ovarian granulosa-stromal cells tumors. Mod Pathol (1995) 0.86
Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. Eur J Cell Biol (2003) 0.83
Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology (2003) 0.83
It's not my fault, blame it on my microenvironment. Differentiation (2002) 0.83
Markers for the development of early prostate cancer. J Pathol (2003) 0.76
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Modeling tissue morphogenesis and cancer in 3D. Cell (2007) 7.49
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
A Rac switch regulates random versus directionally persistent cell migration. J Cell Biol (2005) 4.40
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell (2011) 3.37
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell (2003) 2.90
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Bacterial-derived uracil as a modulator of mucosal immunity and gut-microbe homeostasis in Drosophila. Cell (2013) 2.36
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther (2003) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol (2009) 2.16
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res (2010) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol (2005) 2.02
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A (2008) 1.97
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (2010) 1.86
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol (2005) 1.77
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res (2010) 1.75
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res (2006) 1.71
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res (2002) 1.66
BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res (2006) 1.65
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol (2003) 1.60
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther (2004) 1.58
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res (2010) 1.55
Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. Dev Biol (2005) 1.49
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res (2010) 1.46
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat (2002) 1.44
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet (2008) 1.43
DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer (2002) 1.41
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat (2008) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem (2002) 1.36
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet (2003) 1.36
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet (2011) 1.34
Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res (2003) 1.34
Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 1.33
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer (2006) 1.32
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther (2005) 1.32
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res (2009) 1.31
Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol (2003) 1.31
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res (2011) 1.29
Single-incision laparoscopic cholecystectomy: a comparison with the gold standard. Surg Endosc (2011) 1.29
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J Biol Chem (2003) 1.27
Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods Mol Biol (2009) 1.27
Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr Protoc Cell Biol (2007) 1.27
Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol (2002) 1.26
Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat (2009) 1.26
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res (2006) 1.26
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res (2005) 1.26
Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol (2007) 1.24
FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer (2011) 1.24
Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol (2007) 1.24
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.23
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res (2003) 1.21
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat (2006) 1.19
Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene (2002) 1.19
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer (2011) 1.18
Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. PLoS Genet (2011) 1.18
Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res (2007) 1.17
Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci (2003) 1.17
Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer (2009) 1.17